GSK and Genmab Announce Topline Results from the Concluded Pivotal Trial of Arzerra (Ofatumumab) in Fludarabine and Alemtuzumab Refractory Chronic Lymphocytic Leukemia

London, UK; Copenhagen, Denmark; August 9, 2010 –
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today
topline results from the concluded pivotal trial of ofatumumab in
patients with fludarabine and alemtuzumab refractory...